Pharmaceutical company Lupin announced the introduction of a generic drug for treating urea cycle disorders in the US. The medication is prescribed for long-term treatment of individuals with Urea Cycle Disorders (UCDs) whose conditions cannot be sufficiently controlled through dietary protein limitations and/or amino acid supplements alone.

This introduction represents another important achievement for Lupin as the company continues to broaden its specialized and complex generic drug offerings in the American marketplace. 

The Glycerol Phenylbutyrate Oral Liquid, 1.1g/mL, provides a crucial treatment alternative for individuals affected by UCDs—a collection of uncommon inherited conditions that impair the body's capacity to eliminate ammonia from the blood.

Also Read: Will South Australia's Fruit Fly Eradication Methods Bear Fruit for its Horticulture Industry?

The company's stock was down 0.37 percent, trading at 1,932.85 per share on the BSE.

The Mumbai-headquartered company stated it has released an authorized generic form of Ravicti (Glycerol Phenylbutyrate) oral liquid, 1.1g/mL, in the US market.

 

Also Read: Can Nigeria’s New Industry Policies Uplift the Country's Textile Industry?

Lupin Limited stands as a worldwide pharmaceutical company based in Mumbai, India, maintaining operations across more than 100 global markets. 

The organization's product range encompasses branded and generic medications, sophisticated generics, biotechnology solutions, and active pharmaceutical ingredients.

The company has established recognition for its proficiency in various therapeutic fields including respiratory care, cardiovascular treatment, diabetes management, infection control, digestive health, neurological disorders, and women's healthcare. 

Also Read: Apiculture: A Boon to Mankind

Lupin maintains 15 advanced production facilities and seven innovative research facilities internationally, with a workforce exceeding 24,000 employees.

In addition to its pharmaceutical operations, Lupin enhances its commitment to comprehensive healthcare delivery through its subsidiary companies—Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions—focused on enhancing patient care and expanding accessibility to superior healthcare services.